Fresh Equities
Offers
Learn
PHARMAXIS LTD

INVESTOR PRESENTATION - PHARMAXIS LTD

ASX:PXS

PHARMAXIS LTD

Health Care

Pharmaxis Limited (PXS) is a specialty pharmaceutical company involved in the research, development and commercialisation of therapeutic products for chronic respiratory disorders. PXS has two approved products: Bronchitol for cystic fibrosis and Aridol diagnosis of asthma; and four products in development: PXS-4728, LOX platform technology Orbital, ASM8. Headquartered in Sydney at its Frenchs Forest manufacturing facilities, Pharmaxis also has offices in Europe and the United States. Former Names Pharmaxis Limited PXS (11/11/2003)

Read more

Market Cap

31.71m

Price at Close

$0.08

4w avg. Volume

599.12k

4w avg. Turnover

$55.63k

Announcements
announcementt+2 movementdate
  • Appendix 2A - Exercise of Employee Options

    Issued Capital

  • -

    17 Sep 2020

-

17 Sep 2020
  • Date of Virtual AGM and Closing Date for Director Nomination

    Notice Of Meeting

  • -2.44%

    16 Sep 2020

-2.44%

16 Sep 2020
  • Boehringer Ingelheim discontinues development of BI 1467335

    Progress Report · Market sensitive

  • +2.50%

    06 Sep 2020

+2.50%

06 Sep 2020
  • Pharmaxis Awarded $1M Australian Government Grant

    Progress Report · Market sensitive

  • +1.03%

    02 Sep 2020

+1.03%

02 Sep 2020
  • Appendix 2A - Employee Option Exercise

    Issued Capital

  • +6.06%

    24 Aug 2020

+6.06%

24 Aug 2020
  • Appendix 2A - 2020 Employee Share Plan Grant

    Issued Capital

  • +6.06%

    24 Aug 2020

+6.06%

24 Aug 2020
  • Ceasing to be a substantial holder from AEF

    Shareholder Details

  • +6.06%

    24 Aug 2020

+6.06%

24 Aug 2020
  • FDA Gives Green Light to Start Myelofibrosis Phase 2 Study

    Progress Report · Market sensitive

  • -8.70%

    19 Aug 2020

-8.70%

19 Aug 2020
  • Change in substantial holding from AEF

    Shareholder Details

  • -9.09%

    18 Aug 2020

-9.09%

18 Aug 2020
  • Appendix 2A - Exercise of employee options

    Issued Capital

  • 0.00%

    14 Aug 2020

0.00%

14 Aug 2020
Market Data

Current Price

$0.08

52WK HIGH

$0.285

52WK LOW

$0.053

1YR RETURN

-63.64%

1YR RETURN VS. SECTOR

-103.04%

90 DAY RETURN

+15.94%

ASX RANK

1,219

/2,019

SECTOR RANK

21

/31

SHARES OUTSTANDING

396.41m
ASX:PXS

PHARMAXIS LTD

Health Care

Pharmaxis Limited (PXS) is a specialty pharmaceutical company involved in the research, development and commercialisation of therapeutic products for chronic respiratory disorders. PXS has two approved products: Bronchitol for cystic fibrosis and Aridol diagnosis of asthma; and four products in development: PXS-4728, LOX platform technology Orbital, ASM8. Headquartered in Sydney at its Frenchs Forest manufacturing facilities, Pharmaxis also has offices in Europe and the United States. Former Names Pharmaxis Limited PXS (11/11/2003)

Read more

Market Cap

31.71m

Price at Close

$0.08

4w avg. Volume

599.12k

4w avg. Turnover

$55.63k

ASX:PXS is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Live Chat

Research
Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.